We offer the services for in vitro and in vivo models to improve the efficacy and safety evaluation for new drugs for biotechnology, pharmaceutical and consumer healthcare companies. Our expertise in developing predictive preclinical models helps to reduce the time and cost of product development and minimize the risks of downstream testing.
Customized assays with
proprietary 3D cell models
Highly multiplexed phenogenomic pathway profiling technologies for genetically complex brain disorders
Liver models for drug efficacy
and safety evaluations
Toxicology tests that meet
international regulatory requirements
Assays co-developed with leading
academics and pharmaceutical companies
Highly experienced
operations team
.Patient-derived cancer organoids
.Human Kupffer cells-hepatocyte co-culture model
.Airway epithelium model
.Skin model (Non-GLP)
.Neuronal pathway profiling
.Reporter assay for GPCR binding analysis
.IPSC-derived neural disease models (schizophrenia, genetic and Diabetic
Neuropathy models)
Business
TEL : +82-2-551-7700
FAX : +82-2-551-7701
business@knax.co.kr
R&D
TEL : +82-31-5180-3184
FAX : +82-31-5180-3185
rnd@knax.co.kr
IP holdings
BGX Life Science
(wholly owned subsidiary):